semaj83/ctmatch_classification huggingface dataset:
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Glaucoma An occludable angle was defined as one in which less than 90° circumference of the pigmented trabecular meshwork was visible. Persons in whom primary angle-closure was suspected (PACS) had an occludable angle and no other abnormality. Primary angle closure (PAC) was diagnosed in persons with a normal visual field and optic disc but having an occludable angle and evidence of angle dysfunction. Dysfunctional features included elevated IOP (>19 mm Hg) or a positive darkroom-prone provocation test, peripheral anterior synechiae, pigment smearing in superior drainage angle, sequelae of acute angle closure (iris whorling or glaukomflecken), or a clear history of symptomatic angle closure with evidence of a peripheral iridectomy. An IOP of 19 mm Hg was chosen by taking the mean +2 SDs from other data on Sino-Mongoloid people. Primary angle-closure glaucoma was diagnosed in subjects with an occludable drainage angle and glaucomatous optic neuropathy with compatible visual morbidity. Optic neuropathy was defined as a CDR of 0.7 or more, or asymmetry of 0.2 or more. In early to moderate cases (CDR of 0.7 or 0.8 or asymmetry of 0.2), a reproducible visual field defect was required to confirm the diagnosis. In advanced cases (CDR >=0.9 or CDR asymmetry >0.3), perimetric evidence of visual loss was not an absolute requirement. Primary angle-closure glaucoma was diagnosed if the disc was not visible, but iris stromal atrophy and whorling were seen in conjunction with a visual acuity less than 20/400  Individuals are excluded if there is known ocular disease or insult that could predispose to myopia, such as retinopathy of prematurity or early-age media opacification, or if they had a known genetic disease associated with myopia, such as Stickler or Marfan syndrome
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Schizophrenia Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) for schizophrenia Ages between 18 and 65 Informed consent Weight gain of at least 1.5 kg in the first 4 weeks A sufficient understanding to participate adequately in the weight management program Patients must agree to cooperate with all tests and examinations required by the protocol Each patient must understand the nature of the study and must sign an informed consent document  Serious, unstable somatic illnesses Illnesses associated with weight gain including renal and endocrine diseases Weight change greater than 3 kg in the preceding three months Weight gain less than 1.5 kg in the first 4 weeks
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 6.0-20.0,  Posttraumatic Stress Disorder Depression Admission to the Shriners Hospital or Massachusetts General Hospital for an acute burn, injury, or reconstructive surgery following a burn Between the ages of 6 years Recent experience of an acute burn, injury, or surgery meeting the Diagnostic and Statistical Manual(DSM-IV) A1 stressor criterion Child's response to the stressor meets Diagnostic and Statistical Manual(DSM-IV) A2 response criterion Proficiency in either English or Spanish  No memory of the injury Current use of an anti-depressant Known hypersensitivity to sertraline Diagnosis of Bipolar Disorder Diagnosis of PTSD Mental Retardation Traumatic Brain Injury New onset or marked worsening of a seizure disorder
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 15.0-999.0,  Substance-Related Disorders Hepatitis Documented HCV antibody seroconversion within the 12 months prior to study entry Serum positive for HCV Meets hematologic, biochemical, and serologic at entry visit Thyroid stimulating hormone within normal limits Hepatitis B surface antigen negative Reads at an eighth grade reading level Willing to use adequate contraception for the duration of the study Plans to remain in the study area for 12 months  Positive test for Hepatitis A antibodies, Hepatitis B antibodies, or HIV antibodies Suspected hypersensitivity to pegylated interferon Liver disease Hemoglobinopathies Immune mediated disease Significant cardiac or pulmonary disease Uncontrolled seizure disorder Renal insufficiency with serum creatinine levels greater than 11.5 mb/ml or less than 60 mb/ml History of thyroid disease Active gout
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Myelodysplastic Syndromes diagnosis myelodysplastic syndrome (primary or secondary) based on cytopenia in at least 1 cell line + dysplasia in 2 cell lines (and no other cause (especially deficiencies)) and a pathologic anatomic diagnosis after bone marrow punction refractory anaemia (RA): blood: ≤ 1% blasts, ≤ 1 x 109 monocytes; bone marrow: < 5% blasts, ringed sideroblasts ≤ 15% of the erythroid cells refractory anaemia with ringed sideroblasts (RARS): blood: ≤ 1% blasts, ≤ 1 x 109 monocytes; bone marrow: < 5% blasts, ringed sideroblasts > 15% of the erythroid cells refractory anaemia with excess blasts (RAEB): blood: < 5% blasts, ≤ 1 x 109 monocytes; bone marrow: blasts ≥ 5 -≤ 20% chronic myelomonocytic leukaemia (CMML): blood: >1 x 109/l monocytes, <5% blasts; bone marrow: blasts < 20%, increase of the monocytic component erythrocyte transfusion need working knowledge of the national language written consent for participating this study (informed consent)  candidate for bone marrow or organ transplantation medication: growth factors (GM-CSF), or EPO patients who will receive an intensive chemotherapeutic treatment with a cytopenia, expected longer than 2 weeks refractory anaemia with excess blasts in transformation (RAEB-t): blood: ≥ 5% blasts or Auer rods; bone marrow: or blasts > 20 < 30% or Auer rods pregnancy at the moment of patients with congenital severe haemolytic anaemia, like thalassemia or sickle cell anaemia patients with AIDS or a severe congenital or acquired (e.g. iatrogenic) immunological disorder severe active infections at the moment of
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 8.0-17.0,  Hypothyroidism Patients should have clinical and biochemical evidence of hypothyroidism, T4 less than 5.0 ng /dl , fT4 less than 1.0 mcg/dl and TSH of more than 10. Patients with prolonged hypothyroidism should have growth failure and delayed bone age of at least 2 SD from the mean. Patients with short term hypothyroidism should have normal growth velocity and bone age. 2. Females 8 to 16 years old. 3. Males 9 to 17 years old. 4. Patients without any chronic medical conditions. 5. Availability of a parent or guardian to attend study visits with the patient and to be actively involved in the patient treatment plan. 6. Give written informed consent prior to any study specific screening procedure with the understanding that the patient has the right to withdraw from the study at any time without penalty  Taking medications that affect their growth. (eg. Systemic corticosteroids, anabolic steroids) 2. Experiencing other health problems/conditions that affect their growth rate such as growth hormone deficiency, Cushing Syndrome, rickets, and chronic diseases. 3. Patients with any condition that is a contraindication for GH therapy would conditions such as an active tumor, impaired glucose tolerance, neurofibromatosis (worsening of neurofibromatosis), and hypertrophy of tonsils and adenoids with sleep apnea. Contraindications for patients for GNRHa therapy would a severe systemic reaction to GNRHa which is rare, osteopenia, and osteoporosis, because delaying puberty will worsen the condition. 4. Moving to a location that the patient will not be able to be followed by a pediatric endocrinologist. 5. Patient is not willing to continue with the study. -
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 12.0-18.0,  Overweight Obesity BMI >85th% for age and sex Weight gain over the last 6 months of >5% than expected on the growth curve 17 years of age  Subjects with intolerance to dairy products (e.g., lactose intolerance) will be excluded from entering into the study Subjects must not have a history of clinically significant cardiac disease, congenital heart disease, any clinically significant abnormal cardiac condition, or be known to have a clinically significantly abnormal ECG. Specifically excluded conditions coronary artery disease, clinically significant cardiac arrhythmias, and congestive heart failure Subjects must not have a history of anorexia nervosa, untreated hypothyroidism (TSH greater than 4.0 mU/L for a second generation test), malignancy, pathophysiologic or genetic syndromes associated with obesity (i.e., Cushing's syndrome, Turner's syndrome, Prader Willi syndrome), major psychiatric illness such as bi-polar disorder, ADD, major depression, bulimia, schizophrenia, or psychosis Subjects may not participate in any weight management program, except for that in this study, during this pilot. Subjects may not use prescription or over-the-counter (or herbal) weight control medication during the trial Subjects must not have a history of alcohol or drug addiction or substance abuse within the previous 2 years
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 20.0-50.0,  Schizophrenia Subjects with Schizophrenia Diagnosed with schizophrenia Male Age 20-50 Right handed  No current or past drug or alcohol problems (dependance or abuse) Not color blind Control Subjects Male Age 20-50 Right handed No current psychiatric problems No current or past drug or alcohol problems Not color blind
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Pregnancy Hypothyroidism women with a prior diagnosis of hypothyroidism, currently receiving levothyroxine therapy less than 8 weeks pregnant  cardiac disease, renal failure not euthyroid biochemically within 6 months pre-pregnancy
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 15.0-65.0,  Craniocerebral Trauma Criteria:Patients who have sustained a traumatic brain injury who have completed their inpatient rehabilitation at either of the three Sydney Metropolitan Brain Injury Units (Liverpool, Ryde or Westmead) will be included in this study if they have sustained a very severe or extremely severe traumatic brain injury have had a hospital admission of > 1 month are able to walk independently at > 1 m/s on discharge are able to commit 3 hours per week to a fitness programme live within the area serviced by the 3 units  have a concurrent medical condition for which moderate to high intensity exercise is contraindicated are still in Posttraumatic Amnesia (PTA) have cognitive or language problems that affect their ability to understand verbal instructions have behaviour problems not suitable for a fitness centre environment
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 15.0-70.0,  Autoimmune Thyroiditis Hashimotos Thyroiditis Clinically approved AIT patients who do not use any medication other than LT4 to keep TSH in the lower half of normal range  Any kind of drug use other than LT4 or any kind of known pathology which may effect GIS absorption
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 15.0-40.0,  Eating Disorders Diagnosis of an eating disorder or eating disorder not otherwise specified (except for binge eating disorder), as defined by the Diagnostic and Statistical Manual of the American Psychiatric Association Agrees to remain in IOP treatment for at least 3 weeks Seeking treatment in one of the Renfrew Center's outpatient programs located in the Philadelphia area  Diagnosis of eating disorder not otherwise specified, including binge eating disorder Diagnosis of a psychotic disorder Transferred to inpatient treatment during the IOP stay because of worsening health
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Induced Abortion Women presenting for medical abortion who consent to participate Possibility of final gestational age of less than or equal to 63 days General good health Willing to provide contact information for purposes of follow-up  Conditions which contraindicate the use of mifepristone or misoprostol Women presenting for medical abortion who do not consent to participate
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Hypothyroidism Defined group of women who tested positive for post partum thyroiditis in 1985 Control group randomly picked from those who tested negative
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 12.0-32.0,  Cystic Fibrosis Related Diabetes Cystic fibrosis patients aged 12-32 years Impaired glucose tolerance or CFRD defined as fasting blood glucose (FBG) and post-prandial blood glucose (pp) equal to: FBG <126 and pp 151-200, or FBG <126 and pp >200, or FBG >126 and pp >200 Type 1 diabetes control patients aged 12-32 years  Colonization with Burkholderia cepacia currently on corticosteroid medication pregnant medically unstable Unable to understand the insulin pump directions
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Hypogonadism Total testosterone level <240 ng/dL Serum LH and FSH levels within normal limits  Elevated prolactin Evidence of Benign Prostatic Hypertrophy History of or current breast cancer, prostate cancer, abnormal DRE or elevated PSA or any other malignancy Clinically significant endocrine/metabolic or cardiovascular disease Significant polycythemia
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pulmonary Embolism Patients >= 18 years of age with pulmonary embolism and cardiogenic shock, defined as a systolic arterial pressure <= 90 mmHg, a drop in systolic arterial pressure >= 40 mmHg for >= 15 minutes, or ongoing administration of catecholamines for systemic arterial hypotension 2. Subtotal or total filling defect in the left and/or right main pulmonary artery due to massive PE, as assessed by chest computed tomography or by conventional pulmonary angiography 3. Right ventricular dysfunction on echocardiography: RV systolic hypokinesis and/or RV dilation (optional) 4. Failed thrombolysis or at least one of the following contraindications to PE thrombolysis present Active bleeding History of intracranial bleeding Surgery, delivery, organ biopsy, puncture of a non-compressible vessel within 10 days History of stroke Gastrointestinal bleeding within 10 days Significant trauma within 15 days Head injury requiring hospitalization within 1 year Active cancer with known hemorrhagic risk Neurosurgery or ophthalmologic surgery within the past year  Systemic (paradoxical) embolism in the presence of an atrial septal defect or patent foramen ovale 2. Free floating right heart thrombi, left heart thrombi 3. Life expectancy due to underlying disease less than one month